George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
Theres definitely something big going on in the background for sure .
Like you say - you don't change your Chief Medical Officer , and put her on the board , along with adding Bayers oncology business head honcho , then appoint an interim CMO ( of high calibre) , all at the same time in a study when you are getting absolutely stunning data , which is coming thick and fast , with full recruitment , without good reason .
You then announce a week in advance that you will update everyone with the latest data and your plans for the next 6-9 months .
So update coming next Weds .
I wonder if they'll release the info beforehand . Back in July it came on the same day .
So a week to wait I'd say .
Should be good otherwise why promote its arrival .
Looking forward to it ;-)
Back in here again . This time at 9.47p .
Bit of a discount from the 50p days when I first dipped my toe in .
Yes , the new NED certainly has an incentive to get this higher .
And at £19.97m Mcap - certainly room to grow .
Plays ok for me on the Vox website.
He sounds confident ( as you would expect) .
He does know his onions , on how to get this company and the drugs through to approval .
Good to have a guy at the helm who is not just concerned about the science , but on really not missing the opportunities .
Faron recently announced they planned to file for BLA in 2025 a while ago , and that didn't do them or their SP any harm - in fact it cemented the robustness of the data they have and the confidence in the plan.
Like Dogs says - they'll be bought out / partnered up way before then $$$
I don't watch the Sp like a hawk , and you never can time every top up perfectly . I know the SP is being decimated , and having a long term plan here , I just see that as helping me build a position .When I have some funds , I take a look , and if the prospects are still as attractive , I add away .
I guess I could sit and just wait with a load of cash for the final low point - but how am I going to time that ?
Got my average down again today - so that's good enough for me .
Just had a nice top up again .
6.34p
Crazy that last time the SP was this low was April 2020 - when GGP were still just scratching the surface so to speak .
So much value added in those 3 and a half years .
Months away from hitting the ore now , yet here we are at 6.5p .
Every month I'm adding more while we are down here .
One benefit of having read every document since 2020 is that buying shares at this price is even more pleasing .
I think the current uncertainty in the markets , and the fact that it is getting harder to raise money means that the Nas may be on the back burner for now ( as far a value for money for shareholders ). It was wise to prepare for it , which I'm sure they have - so that should it be needed , they could go down that route .
But its only been in the last couple of months that this stunning Bexmab data has changed the landscape .
All of a sudden we have Christine Roth from Bayer appear on the board .
MLF moves away from CMO onto board .
A new interim CMO.
Something is cooking , and we haven't seen the finished article yet .
FDA meeting was supposed to be Q3 - that would lay out the pathway for Bex ( accelerated Approval ?)
Have they had it yet ?
These big Pharma takeovers are often triggered by something smaller finally getting someone to pull the pin .
Bexmab may be that .
In the end , I think whoever makes a move I think will be wanting not just the AML market for Bex , but the whole platform .
Because that's where the big money will be made .
Https://www.youtube.com/watch?v=j6wNZwnZB-4
Good recap of where Faron are .
'Very Rare and exciting to get such good data '
MLF - more patients onbaord in US - and more good data to come in coming months . Talking to new sites also .
P2 will need 60-100 patients - looking forward to getting it underway .
Inflection point - other companies have realised they need new immunotherapy strategies - they are very involved in discussions .
Asked about an IPO - today - market is tough today and maybe not best time for it ( unless you have a great set of data )
Markku still coy on what is happening in the very short term - no news on funding for P2 - how its happening .
Perhaps this interview was done a while ago , not sure .
I expect CR will have a view on that lol .
CR Bio is now up on the webpage - and they slotted her in right at the top ( not that means anything right ? )
https://www.faron.com/about-us/leadership-and-board?tab=board-of-directors
Ms. Christine Roth is a pharmaceutical executive with over three decades of experience in the industry. She has played key roles in the development and launch of several therapies, including the first immune-oncology therapy and intentionally designed targeted therapy combinations. Her career includes leadership positions at major pharmaceutical companies, such as Novartis, Bristol-Myers Squibb, GlaxoSmithKline (GSK), and most recently, Bayer AG, where she serves as the Executive Vice President of the Oncology Strategic Business Unit focussing on precision molecular oncology, next-generation immuno-oncology medicines, and radioligand therapies. At GSK, she was responsible for the rebuild of the oncology business, including the integration of assets following the acquisition of Tesaro. Ms. Roth’s expertise extends across various therapy areas, including Oncology, Cardiovascular, Metabolic, and Infectious Diseases. She is actively involved in industry associations, such as the American Society of Clinical Oncology and the American Society of Hematology. She holds a Bachelor’s degree in Chemistry from the University of North Carolina at Chapel Hill.
I watched the meeting , and as usual SD is being as honest as possible , and putting himself out there .
Lots going on - so he's hardly going to spill any beans that he doesn't have to .
I'm not bothered about whether he buys a pile of shares at 6p or 14p .
He's had some in the past to tick the box . Personally , I think he's got bigger things to get on with . He isn't a stock trader - he's a gold explorer/producer MD . His skin in the game is his reputation . He'll make plenty of money ( and already is ) and more so when Greatland moves up to the next level .
We are now months ( not years ) away from hitting the good stuff , and that's when the wheels will start moving a lot quicker .
Let's get the Newmont takeover done , and see where we go .
As SD said - it was a goldilocks timing in relation to Telfer .
Gold price will be our friend over the next 10 years .
All we have to do it sit back and let it happen .
As always , many AIM pharma shares are viewed as almost toxic by the market , until they pull a rabbit out of the hat .
Well , at Faron we can see the ears and a nose poking out .
Hopefully not too long until the final reveal !
I don't recall any reason being given .
But my assumption/hope is that her job as CMO was to get Bax to stage where they could sell/partner up . At which point there would be a fresh team/or even company taking the lead ( and with Faron getting a huge payoff ).
She is remaining with Faron as part of the board ( and remaining a key part of the team ) - plus we have the Bayer big shot Christine Roth joining tomorrow - a huge stamp of approval from a Big Pharma .
The interim position announced today - also fits in nicely with the theory that another big change up is coming .
Birge has more than 30 years’ experience in global R&D, spanning all aspects of early and late drug development, including strategic, clinical, regulatory and market access.
https://www.transcrip-group.com/team/birge-berns/
Another quality hire - but why Interim ?
Is the plan to change again , or is this common .
Suggest to me that they don't expect the role to be long term , as things will be changing again shortly ?
New Partner will want to take the lead ?
Either way - its good to have DR Berns onboard - and big thanks to MLF for her work .
While at Johnson & Johnson, Dr. Berns established and led the European clinical hemato-oncology group for Centocor, the J&J Immunology group, devising early development strategies for biological molecules in a wide range of oncology indications, and writing the supporting clinical and regulatory documents. She maintains close ties with the Institute of Cancer Research/Royal Marsden Hospital in the UK where she obtained her Master's degree in Oncology and continues to teach on this course.
Dr Berns is currently VP, Head of Clinical Development & Regulatory Strategy at tranScrip Limited, a strategic drug development partner that provides bespoke drug development services to pharma clients. She also serves as Chair of the Policy & Communication Group of the Faculty of Pharmaceutical Medicine, UK.
"Bexmarilimab has the potential to usher in a new era of cancer treatment for patients in relapses/refractory acute myeloid leukemia and myelodysplastic syndromes that face scant treatment options," said Dr. Berns. "With my long-standing expertise in all aspects of early and late-stage drug development, including strategic, clinical, regulatory and market access, I am keen to apply my skillset to accelerate the development of bexmarilimab."
Faron business development guy also published recently a research article as to how FDA fast track designation can boost a company's share price ( as if we didn't know lol ) . But it shows how even the improved likely hood of forthcoming market approval can boost the SP by 100% .
Every company is different mind you - some will have more potential for their pipeline than others .
Good to see that Faron are working in unison in their mindset of what they have .
Should they hit the big time as we expect - they will be a role model for up and coming small biopharma .
https://www.sciencedirect.com/science/article/abs/pii/S1359644623002878
Oh well , whoever this chump is , he facilitated a small top up for me at a nice price .
Amazing that after all this news on the trial , people can still rock up and buy these shares for about a quid .
One day soon , I'm pretty sure that will all change ;-)
I quite like to see a rocket ( made of commas etc) .
Been a while since we've had cause to , unless it was a pic of the Challenger .
Anyway - news of the day in my household is that my pile of GGP is actually in the blue !
enjoying the moment lol